Partnering
Collaborators:
IF YOU’RE A POTENTIAL PARTNER
Series A, corporate, foundation or government funding and collaboration, MACH-1 initial clinical programs for lead influenza and Covid-19 vaccine assets
DNA and mRNA clinical vaccine candidates in need of optimized formulation and delivery